Navigation Links
Teach For America and Lilly Launch Program to Match Lilly Employees with Teachers in Underserved Public Schools
Date:10/28/2008

undamental changes necessary to ensure educational excellence and equity. For more information, visit http://www.teachforamerica.org.

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com.


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Struggling male readers respond better to female teachers
2. Tips for Parents: Teaching Children to Resolve Conflicts
3. Vatican Affirms Church Teaching on Nutrition and Hydration for Individuals In Vegetative State
4. New Seminar Series from Activator Methods Teaches Doctors a Unique Approach to Improving Nations Chiropractic Care: Focus on the Patients
5. 10th Anniversary of Revolutionary Teaching Approach that Offers the Severely Disabled the Gift of Self-Expression - Through Painting
6. Curtailing School Violence: National Mental Health Experts Outline What Teachers Need to Know
7. TriWest Contributes $25,000 to Iowa National Guard Fund and Sponsors Education for Teachers of Military Children
8. A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks
9. Safe Crossing Week 2007 Teaches Kids How to Behave Safely Around Trains
10. Inspirational Medical Teachers Honored with Mentor Awards from the American Society of Hematology
11. This Holiday Season, Teach Your Kids the Science of How Drinking Alcohol Can Hurt Them

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2009)...ause donated cells to attack recipient,s tissue, s...Day News) -- Researchers are reporting that a gene... that someone who,s had a bone-marrow transplant w...t disease. , The immune system-related complic...the variation and the donor does not. , When t...
(Date:11/22/2009)...NGTON, Nov. 21 Congress...ment upon the United States Senate,s vote tonight ...islation: ,, "Senators Arlen Specter and Bob Ca...ennsylvanians for casting stand-up, critical votes... historic Affordable Health Care Reform legislatio...
(Date:11/21/2009)...SHINGTON, Nov. 21 A reg...e onchocerciasis (river blindness) in the Americas...isease in recent years, as evidenced by a 31% decr...rug administration in six endemic countries. Resu... of the American Society of Tropical Medicine and ...
(Date:11/21/2009)... HAPPYneuron,s most popular and addictiv... and iPod Touch. , Mounta...on,s most popular and addictive game, SplitWords, ...it Words is designed to help banish that ,tip of t...iPhone brain game challenges the brain by encoura...
(Date:11/20/2009)...NCETON, NJ, Nov. 20 /PRNewswire-FirstCall/ - NUCRY...ecial Meeting of Shareholders will be held on Mond...is to consider approval of two special resolutions...uthorize the sale of all or substantially all of t...rovided for in the asset purchase agreement dated ...
Breaking Medicine News(10 mins):Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 2Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 3Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 4Health News:HAPPYneuron releases iPhone Brain Game 2Health News:HAPPYneuron releases iPhone Brain Game 3Health News:NUCRYST Announces Special Meeting of Shareholders 2Health News:NUCRYST Announces Special Meeting of Shareholders 3
...2 Perot Systems,Corporation (NYSE: PER ) and Sur...eement in which Perot Systems will implement advan...r business growth. Through this,agreement, Perot S...ountry. Perot Systems, services will include:,stra...
...a Motor Co., Ltd. will showcase an,experimental mo... walking,for the elderly and other people with wea... on Barrier Free Equipments & Rehabilitation for,t...w.newscom.com/cgi-bin/prnh/20080422/LATU095A ), D...
... 2008 Help is on the way for patients who have un...om chronic pain in their backs and legs, thanks to...pain management specialists. , Called a hybrid ...pheral nerve field stimulation (PNFS). This lates...
...ity, may abolish post-operative arthritic knee pai...ective surgery to repair a common sports-related k...nt), is now available in Michigan., "This innovat...o a degree never seen before with traditional ACL,...
...ints to a new strategy for preventing or possibly ...organ and tissue damage researchers at the Unive...have determined that a molecule called Epac (Excha...ine edition of the Proceedings of the National Aca...
...OrbusNeich,s Genous Bio-engineered,R stent will be...sty Summit,TCT 2008 Asia Pacific., The symposium,...on,Center of Sheraton Grande Walkerhill Seoul Hote...al Progenitor Cell Capture Technology and Beyond" ...
Other Medicine News:Health News:Perot Systems and Surgical Care Affiliates Sign Five-Year Agreement to Implement Advanced Technology Solutions 2Health News:Perot Systems and Surgical Care Affiliates Sign Five-Year Agreement to Implement Advanced Technology Solutions 3Health News:Honda to Showcase Experimental Walking Assist Device 2Health News:Mix of 2 pain-relief procedures can end chronic back and leg pain without drugs 2Health News:Mix of 2 pain-relief procedures can end chronic back and leg pain without drugs 3Health News:Two Michigan Orthopedic Surgeons Pioneer Innovative ACL Surgery with New Benefits for Athletes, Weekend Warriors 2Health News:Two Michigan Orthopedic Surgeons Pioneer Innovative ACL Surgery with New Benefits for Athletes, Weekend Warriors 3Health News:Scientists identify novel way to prevent cardiac fibrosis 2Health News:Symposium at Angioplasty Summit TCT Asia Pacific 2008 Features OrbusNeich's Genous(TM) Bio-engineered R stent(TM) 2
(Date:11/20/2009)... , PLYMOUTH MEETING, Pa., Nov. 20 /PRNewswir... Times article that questions why currently avail...e cancers are being ignored, ECRI Institute, an in...admap to the evidence on Finasteride for Preventi...The November 13, 2009, New York Times article, "...
(Date:11/20/2009)..., MEMPHIS, Tenn., Nov. 20 /PRNewswire-FirstCa...dics Division is pleased to announce the signing o...d States Department of Defense that may lead to th...to revolutionize the treatment of the limbs of sol... year, the Defense Advanced Research Projects Agen...
(Date:11/19/2009)... , ARDEE, Ireland, Nov. 19 War...the pricing of its previously announced secondary ... price to the public of $22.25 per share. The sel...in Capital Partners, DLJ Merchant Banking, J.P. Mo... H. Lee Partners, L.P., certain other institutiona...
Breaking Medicine Technology:ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 2ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 2Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 4Warner Chilcott Prices Secondary Equity Offering 2Warner Chilcott Prices Secondary Equity Offering 3Warner Chilcott Prices Secondary Equity Offering 4CEM Wins Presidential Green Chemistry Challenge Award for the Sprint Rapid Protein Analyzer 12724 1CEM Wins Presidential Green Chemistry Challenge Award for the Sprint Rapid Protein Analyzer 12724 2KV Pharmaceutical Receives Letter From NYSE Regarding Delayed Filing of Its 2009 Annual Report on Form 10 K 49600 1KV Pharmaceutical Receives Letter From NYSE Regarding Delayed Filing of Its 2009 Annual Report on Form 10 K 49600 2KV Pharmaceutical Receives Letter From NYSE Regarding Delayed Filing of Its 2009 Annual Report on Form 10 K 49600 3KV Pharmaceutical Receives Letter From NYSE Regarding Delayed Filing of Its 2009 Annual Report on Form 10 K 49600 4KV Pharmaceutical Receives Letter From NYSE Regarding Delayed Filing of Its 2009 Annual Report on Form 10 K 49600 5KV Pharmaceutical Receives Letter From NYSE Regarding Delayed Filing of Its 2009 Annual Report on Form 10 K 49600 6 New Strategy Eyed for AIDS Treatment 49598 1 New Strategy Eyed for AIDS Treatment 49598 2
...itor, and R7128, nucleoside polymerase inhibitor, ...n patients with hepatitis C - , , NUTLEY, N.J., ...oche, InterMune, Inc. (Nasdaq: ITMN ) and Pharma...esults from their innovative, interferon-free regi...herapy for the treatment of patients chronically i...
...rmed to date will be presented during the Internat...nnual Meeting in Paris, France on April 24, 2009 ...d as an in vitro assessment of cell-mediated imm...erous clinical investigations have contributed to ...g recipients of solid organ transplants. , , (Lo...
Other Medicine Technology:Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 2Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 3Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 4Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 5Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 6Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 7Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 8Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 9Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 10Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 11An Independent Study Reports on the Utility of ImmuKnow(R), the Cylex(TM) Immune Cell Function Assay, for Monitoring Heart Transplant Recipients 2
...cientific principles supporting the effectiveness ...sed upon extensive clinical studies. As a woman ne...vel increases, thereby, elevating the salt in her ...ed to dry, crystalization occurs. The closer a wom...
Gastroccult Gastric Occult and pH Test
SureStep™ FSH Menopause Test (mid-stream)
FSH Home Menopause Test Midstream (Urine)
Medicine Products: